This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeClinical InformationClinical InformationACIP RecommendationsWhat is TicoVac®?What is TBE?Symptoms & Risk FactorsDemonstrated EffectivenessDosing & Administration ScheduleResourcesResourcesMaterialsVideosOrder TicoVac®
Prescribing Information Indication Patient Site
Demonstrated Effectiveness 
 TicoVac® has evidence of real-world effectiveness.1,296–99% Overall field effectiveness in regularly vaccinated persons who completed the primary series in Austria from 2000-2011.1-3Clinical Studies
Neutralization test (NT) seropositivity* rates were determined 21 days after the third dose.2,†
99.2% to 99.6% for subjects 1 through 15 years of age vaccinated with TicoVac®2
98.7% to 100% for subjects 16 years of age and older vaccinated with TicoVac®2In clinical trials with TicoVac®, seropositivity NT ≥ 1:10 (European subtype Neudoerfl TBE strain).Depending on the age group.The field effectiveness of TicoVac® was assessed retrospectively in the entire Austria population.2,3In Austria, TicoVac® effectiveness was calculated for the period 2000 to 2011 by comparing the incidence of TBE cases between vaccinated and unvaccinated subjects.3,4TicoVac® may help to protect against the main TBE virus subtypes.5

Distribution of TBE virus 
Three main subtypes of TBE exist across Europe and Asia: European, Siberian, and Far Eastern, each of which have different attributes that make them distinct.6-8

There are more than 30 countries where TBE or the TBE virus has been found including6:Albania, Austria, Belarus, Bosnia and Herzegovina, China, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Japan, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Mongolia, Netherlands, Norway, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, South Korea, Sweden, Switzerland, Ukraine

TicoVac® may help protect against the main TBE virus subtypes.5

References:Barrett PN, Portsmouth D, Ehrlich HJ. Tick-borne encephalitis virus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Elsevier Saunders; 2013:773-788.TicoVac® (Tick-Borne Encephalitis Vaccine). Prescribing Information. New York, NY: Pfizer Inc. 2021.Heinz FX, Stiasny K, Holzmann H, et al. Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis. 2013;19(1):69-76. doi:10.3201/eid1901.120458Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine. 2007;25(43):7559- 7567. doi:10.1016/j.vaccine.2007.08.024Orlinger KK, Hofmeister Y, Fritz R, et al. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis. 2011;203(11):1556-1564. doi:10.1093/infdis/jir122Dobler G, Erber W, Bröker M, Schmitt HJ, eds. The TBE Book. 4th edition. Global Health Press; 2021.Adelshin RV, Melnikova OV, Karan LS, Andaev EI, Balakhonov SV. Complete Genome Sequences of Four European Subtype Strains of Tick-Borne Encephalitis Virus from Eastern Siberia, Russia. Genome Announc. 2015;3(3):e00609-15. doi:10.1128/genomeA.00609-15Tonteri E, Jääskeläinen AE, Tikkakoski T, et al. Tick-borne encephalitis virus in wild rodents in winter, Finland, 2008-2009. Emerg Infect Dis. 2011;17(1):72-75. doi:10.3201/eid1701.100051Clinical Information
DOSING & ADMINISTRATION SCHEDULE

TicoVac® primary dosing series should be completed at least 1 week prior to potential exposure to TBEV.2

 Learn more about dosing Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TCV-USA-0190
INDICATION AND USAGE TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
IMPORTANT SAFETY INFORMATION
  • TicoVac® should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVac®.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVac®.
  • TicoVac® may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVac®.
  • TicoVac® contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVac® were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVac® were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
Patients should always ask their healthcare providers for medical advice about adverse events.You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.
Please see full prescribing information for TicoVac® here.
Indication TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.Important Safety Information
  • TicoVac® should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVac®.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVac®.
  • TicoVac® may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVac®.
  • TicoVac® contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVac® were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVac® were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
 Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. Please see full prescribing information for TicoVac® here. Indication
TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
You are now leaving PfizerPro  
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367